SUPN's Quality Score fell 1 point on Tue, Nov 10, to 2. Trading went back to normal after a busy day.
Follow SUPN's news. Pro members can get an alert when Supernus files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 4.1% today, while its health care peers are down 1.0%; no story names it yet.
Fell on Nov 3
Down 33% on Nov 3, and still 36% under its Oct 30 close.
“Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader.”
| Long-term trend | −3 |
| Latest filing | 8-K, Nov 2 |
TodayNo story names it yet.
Mon Nov 16: Jefferies 17th Annual London Global…Investor conference · date confirmed.
After its last 4 reports it closed +3.4% on average, higher 4 of 4 times.
No shelf registration or at-the-market program on file in the last three years.
Chief Accounting Officer Woodrow D. Anderson bought 1,500 shares on Aug 27. 19 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
SUPN is #44 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 44 |
Expected to report Tue Feb 23, after the close (in 105 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $226.8M, 18% more than a year ago; a profit of $0.35 a share, from a loss of $0.80.
“This strong growth was driven by an increase in net sales of Qelbree ® , GOCOVRI ® , ZURZUVAE ® , and ONAPGO™.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| United States | $307M | $300M | $267M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 29)
No outlook figures read from this release.
“The increase in the three month period ended September 30, 2026 was primarily due to higher revenues, as well as a decrease in selling, general, and administrative expenses due to the absence of acquisition-related costs associated with the acquisition of Sage in the third quarter of 2025.”
From its results filing (SEC filing · Oct 29)
Sales grew 11% a year over 3 years, fiscal 2022 to 2025.
Its share count fell 2.7% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 29, 2026 | +0.6% | +0.2% | -37.5% |
| Aug 3, 2026 | +13.0% | +3.1% | +6.7% |
| May 5, 2026 | +3.0% | +4.6% | +2.7% |
Sales grew every year from 2022 to 2025, to $1.2B. It made a profit in two of the four years.
RSI 28.3, MACD below signal, below both averages. Not scored.
One insider bought $108K across 2 filings in the last 6 months. No open-market sales on record. The newest:
2 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
Supernus Inc is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The company's commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
“We operate in a highly competitive industry.”
SUPN scores 2 today, which Breakaway calls Below Average. It is #44 of 90 in Pharma by Quality Score, with 2 of 14 chart checks firing. Down 33% on Nov 3, and still 36% under its Oct 30 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
SUPN scores 2 today, which Breakaway calls Below Average (0 to 5). That is #44 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind SUPN's 2.
One insider bought $108K across 2 filings in the last 6 months. No open-market sales on record. The newest is Woodrow D. Anderson, Chief Accounting Officer, who bought $54K on Aug 27. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.